Roivant Sciences Ltd. ROIV
Set alert
35.89 USD -1.02 -2.76%
At close · Nov 2
35.89 0.00 0.00%
After hours · Nov 2, 4:00 PM ET
35.82 Day range 37.29
19.30 52-week range 42.50
- YTD
- +65.39%
- 1 year
- +79.54%
- Open
- 36.95
- Prev close
- 36.91
- Mkt cap
- 25.92B
- Vol
- 5.70M
- Avg vol
- 7.63M
- EPS
- -0.53
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 35.82
- High
- 37.29
- Forward P/E
- -25.78
- Beta
- 1.20
- Short ratio
- 5.65
- Inst. own
- 78.60%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 9, 2026
- 50-d avg
- 36.65
- 200-d avg
- 31.50
- 1y target
- 50.00
2Y chart
Events in this range
- Aug 11, 2025Earnings: -0.25175; estimate -0.2497; surprise -0.82%
- Nov 10, 2025Earnings: -0.20193; estimate -0.3198; surprise 36.86%
- Feb 6, 2026Earnings: -0.24; estimate -0.29954; surprise 19.88%
- May 20, 2026Earnings: -0.2792; estimate -0.28931; surprise 3.49%
- Aug 6, 2026Earnings: -0.33; estimate -0.29962; surprise -10.14%
- Sep 8, 2026Rating: HC Wainwright & Co. · Buy → Buy
- Sep 9, 2026Rating: Guggenheim · Buy → Buy
- Sep 9, 2026Rating: TD Cowen · Buy → Buy
- Sep 17, 2026Rating: Stifel · — → Buy
- Oct 12, 2026Downgrade: Wolfe Research · Outperform → Peer Perform
- Oct 28, 2026Rating: Citigroup · Buy → Buy
Signals (92)
| Name | Date | Ago |
|---|---|---|
| SMA: Bearish | Nov 2, 2026 | 8 hours ago |
| SMA: Bullish | Oct 28, 2026 | 5 days ago |
| SMA: Bearish | Oct 23, 2026 | 1 week ago |
| SMA: Bullish | Oct 21, 2026 | 1 week ago |
| MACD: Buy Signal | Oct 21, 2026 | 1 week ago |
| SMA: Bearish | Oct 1, 2026 | 1 month ago |
| SMA: Bullish | Sep 30, 2026 | 1 month ago |
| SMA: Bearish | Sep 29, 2026 | 1 month ago |
| SMA: Bullish | Sep 28, 2026 | 1 month ago |
| SMA: Bearish | Sep 24, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 22, 2026 | 1 month ago |
| SMA: Bullish | Sep 8, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 8, 2026 | 1 month ago |
| RSI: Overbought | Sep 8, 2026 | 1 month ago |
| SMA: Bearish | Aug 28, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 28, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 27, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 25, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 7, 2026 | 2 months ago |
| MACD: Sell Signal | Jul 14, 2026 | 3 months ago |
| RSI: Overbought | Jun 24, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 15, 2026 | 4 months ago |
| SMA: Bullish | Jun 11, 2026 | 4 months ago |
| SMA: Bearish | Jun 10, 2026 | 4 months ago |
| SMA: Bullish | Jun 9, 2026 | 4 months ago |
| SMA: Bearish | Jun 5, 2026 | 5 months ago |
| SMA: Bullish | Jun 3, 2026 | 5 months ago |
| SMA: Bearish | Jun 2, 2026 | 5 months ago |
| MACD: Sell Signal | Jun 1, 2026 | 5 months ago |
| SMA: Bullish | May 20, 2026 | 5 months ago |
| MACD: Buy Signal | May 20, 2026 | 5 months ago |
| SMA: Bearish | May 19, 2026 | 5 months ago |
| MACD: Sell Signal | May 19, 2026 | 5 months ago |
| MACD: Buy Signal | May 11, 2026 | 5 months ago |
| SMA: Bullish | May 8, 2026 | 5 months ago |
| SMA: Bearish | May 7, 2026 | 5 months ago |
| SMA: Bullish | May 4, 2026 | 6 months ago |
| SMA: Bearish | May 1, 2026 | 6 months ago |
| SMA: Bullish | Apr 30, 2026 | 6 months ago |
| SMA: Bearish | Apr 23, 2026 | 6 months ago |
| MACD: Sell Signal | Apr 23, 2026 | 6 months ago |
| MACD: Buy Signal | Apr 9, 2026 | 6 months ago |
| MACD: Sell Signal | Mar 6, 2026 | 8 months ago |
| MACD: Buy Signal | Mar 4, 2026 | 8 months ago |
| RSI: Overbought | Mar 4, 2026 | 8 months ago |
| MACD: Sell Signal | Mar 3, 2026 | 8 months ago |
| RSI: Overbought | Feb 23, 2026 | 8 months ago |
| RSI: Overbought | Feb 18, 2026 | 8 months ago |
| SMA: Bullish | Feb 6, 2026 | 8 months ago |
| MACD: Buy Signal | Feb 6, 2026 | 8 months ago |
| RSI: Overbought | Feb 6, 2026 | 8 months ago |
| SMA: Bearish | Feb 4, 2026 | 9 months ago |
| SMA: Bullish | Feb 2, 2026 | 9 months ago |
| SMA: Bearish | Jan 30, 2026 | 9 months ago |
| MACD: Sell Signal | Jan 23, 2026 | 9 months ago |
| MACD: Buy Signal | Jan 13, 2026 | 9 months ago |
| MACD: Sell Signal | Dec 26, 2025 | 10 months ago |
| RSI: Overbought | Dec 16, 2025 | 10 months ago |
| MACD: Buy Signal | Dec 15, 2025 | 10 months ago |
| MACD: Sell Signal | Nov 14, 2025 | 11 months ago |
| MACD: Buy Signal | Oct 16, 2025 | 1 year ago |
| MACD: Sell Signal | Oct 10, 2025 | 1 year ago |
| MACD: Buy Signal | Oct 1, 2025 | 1 year ago |
| MACD: Sell Signal | Sep 30, 2025 | 1 year ago |
| RSI: Overbought | Sep 25, 2025 | 1 year ago |
| RSI: Overbought | Sep 5, 2025 | 1 year ago |
| MACD: Buy Signal | Aug 13, 2025 | 1 year ago |
| SMA: Bullish | Aug 12, 2025 | 1 year ago |
| SMA: Bearish | Aug 11, 2025 | 1 year ago |
| MACD: Sell Signal | Aug 11, 2025 | 1 year ago |
| MACD: Buy Signal | Aug 5, 2025 | 1 year ago |
| MACD: Sell Signal | Jul 28, 2025 | 1 year ago |
| MACD: Buy Signal | Jul 14, 2025 | 1 year ago |
| SMA: Bullish | Jul 9, 2025 | 1 year ago |
| SMA: Bearish | Jul 1, 2025 | 1 year ago |
| MACD: Sell Signal | Jun 30, 2025 | 1 year ago |
| MACD: Buy Signal | Jun 20, 2025 | 1 year ago |
| MACD: Sell Signal | Jun 16, 2025 | 1 year ago |
| MACD: Buy Signal | Jun 2, 2025 | 1 year ago |
| MACD: Sell Signal | May 9, 2025 | 1 year ago |
| RSI: Overbought | Apr 30, 2025 | 1 year ago |
| SMA: Bullish | Apr 22, 2025 | 1 year ago |
| MACD: Buy Signal | Apr 14, 2025 | 1 year ago |
| RSI: Oversold | Apr 4, 2025 | 1 year ago |
| MACD: Sell Signal | Mar 27, 2025 | 1 year ago |
| SMA: Bearish | Mar 25, 2025 | 1 year ago |
| SMA: Bullish | Mar 19, 2025 | 1 year ago |
| MACD: Buy Signal | Mar 5, 2025 | 1 year ago |
| MACD: Sell Signal | Mar 3, 2025 | 1 year ago |
| MACD: Buy Signal | Feb 20, 2025 | 1 year ago |
| MACD: Sell Signal | Feb 4, 2025 | 1 year ago |
| MACD: Buy Signal | Jan 23, 2025 | 1 year ago |
Key statistics
- Market cap
- 25.92B
- Enterprise value
- 23.62B
- Trailing P/E
- 0.00
- Forward P/E
- -25.78
- PEG ratio
- 0.00
- Price / sales
- 3441.87
- Price / book
- 6.13
- EPS (TTM)
- -0.53
- Beta
- 1.20
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 7.53M
- Revenue growth
- -33.50%
- Free cash flow
- -1.12B
- Total cash
- 3.84B
- Total debt
- 107.15M
- Return on equity
- -8.52%
- Shares outstanding
- 722.32M
- Short % of float
- 7.56%
- 50-day average
- 36.65
- 200-day average
- 31.50
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 50.00 +39.3% upside
Now 35.89
- Target (low)
- 41.00
- Target (mean)
- 50.00
- Target (high)
- 62.00
Ratings (0m) 13 11 buy · 2 hold · 0 sell
- Strong buy2
- Buy9
- Hold2
- Sell0
- Strong sell0
Next earnings
Nov 9, 2026
Expected Nov 9, 2026. Consensus EPS estimate -0.44866.
Financials — quick view
ROIV Revenue — quarterly 1.44M
ROIV Net income — quarterly -189.84M
ROIV EPS — quarterly -0.26
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 9, 2026 | Sep 30, 2026 | -0.36664 | — | — | — |
| Aug 6, 2026 | Jun 30, 2026 | -0.29962 | -0.33 | -0.03 | -10.14% |
| May 20, 2026 | Mar 31, 2026 | -0.28931 | -0.2792 | +0.01 | +3.49% |
| Feb 6, 2026 | Dec 31, 2025 | -0.29954 | -0.24 | +0.06 | +19.88% |
| Nov 10, 2025 | Sep 30, 2025 | -0.3198 | -0.20193 | +0.12 | +36.86% |
| Aug 11, 2025 | Jun 30, 2025 | -0.2497 | -0.25175 | 0.00 | -0.82% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 28, 2026 | Citigroup | main | Buy | Buy |
| Oct 12, 2026 | Wolfe Research | down | Outperform | Peer Perform |
| Sep 17, 2026 | Stifel | init | — | Buy |
| Sep 9, 2026 | TD Cowen | main | Buy | Buy |
| Sep 9, 2026 | Guggenheim | main | Buy | Buy |
| Sep 8, 2026 | HC Wainwright & Co. | main | Buy | Buy |
About Roivant Sciences Ltd.
Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease; neonatal fragment crystallizable receptor for the treatment of graves' disease, difficult-to-treat rheumatoid arthritis, sjögren's disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythematosus indications; batoclimab, a fully human monoclonal antibody for the treatment of thyroid eye disease; and brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis, and other immune-mediated diseases. The company's lead program consists of mosliciguat, an inhaled sGC activator for the treatment of pulmonary hypertension associated with interstitial lung disease and other cardiopulmonary diseases. In addition, the company offers delivery platforms comprising a lipid nanoparticle (LNP) platform and a ligand conjugate platform. Roivant Sciences Ltd. was founded in 2014 and is based in London, United Kingdom.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United Kingdom
- Website
- roivant.com
News
- Citigroup Maintains Buy on Roivant Sciences, Raises Price Target to $56
- If You Invested $100 In Roivant Sciences Stock 5 Years Ago, You Would Have This Much Today
- Roivant Sciences Ltd. (ROIV) Discusses Phase 3 Results for Brepocitinib in Non-Infectious Uveitis Transcript
- Why Is Roivant Sciences Stock Surging Wednesday?
- Roivant Sciences' Brepocitinib Delivers Positive Phase III Uveitis Results
- 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- Roivant and Priovant Announce Positive Results in CLARITY-1 and CLARITY-2 Phase 3 Trials for Brepocitinib in Non-Infectious Uveitis (NIU)
- Roivant to Report Financial Results for the Second Quarter Ended September 30, 2026, and Provide Business Update on Monday, November 9, 2026
- Roivant Sciences Ltd. $ROIV Stock Holdings Lowered by Assenagon Asset Management S.A.
- Here’s How Much You Would Have Made Owning Roivant Sciences Stock In The Last 5 Years
Your note
Sign in to keep a note on ROIV — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| GLINE MATTHEW | Chief Executive Officer | Sale | Apr 15, 2026 | 16,736,100 |
| GOLD DANIEL ALLEN | Director | Sale | Jun 29, 2026 | 0 |
| KUMAR RAKHI | Officer | Sale | Feb 12, 2025 | 163,264 |
| MANCHESTER KEITH S | Director | Stock Award(Grant) | Sep 15, 2026 | 1,753,460 |
| OREN ILAN | Director | Stock Award(Grant) | Oct 22, 2026 | 124,490 |
| PULIK RICHARD | Chief Financial Officer | Stock Award(Grant) | Apr 19, 2026 | 297,511 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 11.22% | 81,020,390 | 2.91B | Jun 29, 2026 |
| Blackrock Inc. | 6.68% | 48,236,091 | 1.73B | Jun 29, 2026 |
| Morgan Stanley | 5.90% | 42,592,905 | 1.53B | Jun 29, 2026 |
| QVT Financial LP | 3.28% | 23,723,074 | 851.42M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 3.06% | 22,123,198 | 794.00M | Jun 29, 2026 |
| Vanguard Portfolio Management LLC | 3.00% | 21,641,339 | 776.71M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 3.19% | 23,009,528 | 825.81M | Aug 30, 2026 |
| iShares Trust-iShares Core S&P Mid-Cap ETF | 2.67% | 19,297,013 | 692.57M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.21% | 15,987,737 | 573.80M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 1.60% | 11,546,280 | 414.40M | Jun 29, 2026 |
| Invesco Exchange-Traded Fund Trust-Invesco S&P MidCap Momentum ETF | 0.96% | 6,900,746 | 247.67M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Growth Index Fund | 0.92% | 6,658,616 | 238.98M | Jun 29, 2026 |